This article contains some figures that are displayed in color online but in black-and-white in the print edition.
Kim IHPark CKHeo DSKim CYRhee CHNam DH: Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. J Neurooncol 103:595–6022011
Muragaki YMaruyama TIseki HTanaka MShinohara CTakakura K: Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg 115:248–2552011. (Erratum in J Neurosurg 118:
Sampson JHHeimberger ABArcher GEAldape KDFriedman AHFriedman HS: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–47292010
Smith KAAshby LSGonzalez LFBrachman DGThomas TCoons SW: Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 109:Suppl106–1172008. (Errata in J Neurosurg 110:J Neurosurg 111:
Stummer WMeinel TEwelt CMartus PJakobs OFelsberg J: Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 108:89–972012
Stupp RHegi MEMason WPvan den Bent MJTaphoorn MJJanzer RC: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–4662009